Improved tolerability by a modified intermittent treatment schedule of dasatinib for patients with chronic myeloid leukemia resistant or intolerant to imatinib

A small molecule–kinase interaction map for clinical kinase inhibitors

Miles A. Fabian, William Biggs, Daniel K. Treiber et al. · Nature Biotechnology · 2005 · 1.9K citations · Full text

Pharmacy, Medicinal Chemistry, Molecular Biology +12

Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor

Neil P. Shah, Chris Tran, Francis Y. Lee et al. · Science · 2004 · 1.8K citations

Medicine, Oncology, Pharmacology +14

Dasatinib in Imatinib-Resistant Philadelphia Chromosome–Positive Leukemias

Moshe Talpaz, Neil P. Shah, Hagop M. Kantarjian et al. · New England Journal of Medicine · 2006 · 1.8K citations · Full text

Medicine, Hematology, Pharmacology +15

Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia

Hagop M. Kantarjian, Neil P. Shah, Andreas Hochhaus et al. · New England Journal of Medicine · 2010 · 1.6K citations

Medicine, Pharmacology, Pharmacotherapy +10

<i>In vitro</i> Activity of Bcr-Abl Inhibitors AMN107 and BMS-354825 against Clinically Relevant Imatinib-Resistant Abl Kinase Domain Mutants

Thomas O’Hare, Denise K. Walters, Eric P. Stoffregen et al. · Cancer Research · 2005 · 1K citations · Full text

Medicine, Oncology, Pharmacology +10